Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 137

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Systemic mastocytosis+1

Not recruiting

Study of Avapritinib for Patients with Indolent Systemic Mastocytosis Not Adequately Managed by Standard Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Myasthenia gravis

Not recruiting

Study on Cladribine for Treating Seropositive Myasthenia Gravis in Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Uniwersytet Medyczny W Lublinie

Cholangitis sclerosing

Not recruiting

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Transplant rejection

Not recruiting

Study on Efgartigimod for Patients with Antibody-Mediated Rejection after Kidney Transplant

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Dermatitis atopic

Not recruiting

Study on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study Comparing Subcutaneous and Intravenous Human Normal Immunoglobulin for New Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Region Midtjylland

Mucous membrane pemphigoid

Not recruiting

Study on Rituximab and Cyclophosphamide for Patients with Severe Mucous Membrane Pemphigoid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Centre Hospitalier Universitaire Rouen

HIV infection

Not recruiting

Study on the Effects of Abacavir Sulfate and Etravirine in Pregnant Women with HIV

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Abacavir Sulfate
  • Sponsor:Stichting Radboud universitair medisch centrum

Systemic scleroderma

Not recruiting

Study on the Effectiveness of Nintedanib and Tocilizumab for Patients with Systemic Sclerosis and Interstitial Lung Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nintedanib
  • Sponsor:Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher

Conjunctivitis allergic+1

Not recruiting

Study on the Effects of Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Bilastine
  • Sponsor:Inmunotek S.L.

Primary biliary cholangitis

Not recruiting

Study on Golexanolone for Patients with Primary Biliary Cholangitis Experiencing Fatigue and Cognitive Dysfunction

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golexanolone
  • Sponsor:Umecrine Cognition AB

Acute respiratory distress syndrome+3

Not recruiting

Study on Imlifidase for Patients with Severe ANCA-Associated Vasculitis and Lung Bleeding

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.